

Indian Hospitals Industry

ARPOB growth continues to drive industry revenues

MARCH 2024



Highlights





ICRA expects YoY improvement in ARPOB-of 8-10% in FY2024, with a moderation thereafter to 4-6% in FY2025.

Growth in ARPOB supported by better payor and case mix, price increases and continued strong international patient footfalls.



■ The average revenue per occupied bed (ARPOB) of ICRA's sample set of companies¹ is expected to witness healthy YoY growth of 8-10% in FY2024 driven by improved case mix with high-end procedures, annual price revisions, healthy international patient footfalls and higher share of revenues from cash and insurance patients. Given the expected commencement of operations of ~3,400 beds and large base of both FY2023 and FY2024, ARPOB growth is expected to moderate to 4-6% in FY2025.



■ ICRA's sample set of companies are expected to post a healthy YoY growth of 12-14% in revenues in FY2024 supported by stable occupancy of 64-65% and strong ARPOB levels. Revenue growth is expected to remain healthy at 9-11% in FY2025 as well supported by moderate growth in ARPOB and commencement of operations at new hospitals despite decline in occupancy to 61-63%.



■ The operating profit margin (OPM) for ICRA's sample set companies is expected to remain healthy at 22-23% in FY2024. However, the same will contract slightly to 21-22% in FY2025 given the higher fixed expenses incurred at newer hospitals in the initial stages of their operations.



• In an ongoing public interest litigation, the Hon'ble Supreme Court has indicated to the Central Government that if it does not present a proposal to standardise hospital rates for various procedures in line with the Clinical Establishment Act, it will implement Central Government Health Scheme rates across all hospitals as an interim measure. Consequently, any regulatory measure by way of price caps may impact the financial profile of industry players adversely.

ICRA's sample set includes the hospital business of nine listed companies, Apollo Hospitals Enterprise Limited, Aster DM Healthcare Limited (India business only), Fortis Healthcare Limited, Healthcare Global Enterprises Limited, Krishna Institute of Medical Sciences Limited, Max Healthcare Institute Limited, Narayana Hrudayalaya Limited, Rainbow Children's Medicare Limited and Shalby Limited



Name	Designation	Email	Contact Number
Shamsher Dewan	Group Head	shamsherd@icraindia.com	0124 – 4545 328
Kinjal Shah	Co-Group Head	kinjal.shah@icraindia.com	022 – 6114 3442
Mythri Macherla	Sector Head	mythri.macherla@icraindia.com	022 – 6114 3435

















ICRA Business Development/Media Contact Details

Name	Designation	Email	Contact Number
L Shivakumar	Chief Business Officer	shivakumar@icraindia.com	022-61693304
Neha Agarwal	Head – Research Sales	neha.agarwal@icraindia.com	022-61693338
Rohit Gupta	Head Business Development - Infrastructure Sector	rohitg@icraindia.com	0124-4545340
Vivek Bhalla	Head Business Development - Financial Sector	vivek.bhalla@icraindia.com	022-61693372
Vipin Saboo	Head Business Development – Corporate Sector - West & East	vipin.saboo@icraindia.com	022-61693348
Shivam Bhatia	Head Business Development – Corporate Sector - North & South	shivam.bhatia@icraindia.com	0124-4545803
Naznin Prodhani	Head – Media & Communications	communications@icraindia.com	0124-4545860



















© Copyright, 2024 ICRA Limited. All Rights Reserved.

All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



Thank You!

